Bioventus Q2 organic revenue up 6.2%; EPS $0.11 vs loss; reaffirms FY2025 guidance

Bioventus Inc.

2025-Q2 EPS reported $0.07 revenue$271,536,000

Revenue $147.7M (-2.4% reported); organic revenue +6.2%, driven by double-digit growth in Surgical Solutions and Restorative Therapies.
Diluted EPS $0.11 vs loss of $0.40; non-GAAP EPS $0.21, up 31% YoY on lower interest and equity compensation.
Adjusted EBITDA $33.8M vs $34.5M; cash from operations $25.9M, up 71%.
Reaffirmed FY2025 guidance: revenue $560-570M, Adjusted EBITDA $112-116M, non-GAAP EPS $0.64-0.68.
Received FDA 510(k) clearance for TalisMann and StimTrial PNS systems in July 2025, addressing chronic nerve pain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.